Overactive Bladder Treatment Market (Pharmacotherapy, Disease Type) - Reach $5.33Bn by 2028 at 3.1% CAGR with Mirabegron Segment Driving Growth During 2022–2028 | The Insight Partners

The Insight Partners published latest research report on “Overactive Bladder Treatment Market Revenue Report, Trends, Growth, Demand & Forecast to 2028 - COVID-19 Impact and Global Analysis By Pharmacotherapy, and Disease Type”, the global market size is projected to reach USD 5,333.92 million by 2028 from USD 4,295.93 million in 2021. The market is estimated to grow with a CAGR of 3.1% from 2022 to 2028.

Request Sample PDF Brochure: https://www.theinsightpartners.com/sample/TIPRE00004082

Overactive bladder (OAB) is the frequent and sudden urge to urinate which might be difficult to control. OAB can be caused due to abdominal trauma, infection, nerve damage, and certain medications. OAB is common in people aged 65 and older. Women may have OAB after 45 years. The treatment includes changing certain behaviors, medications, and nerve stimulation. According to the National Association for Incontinence data, in 2018, ~200 million people were affected by urinary incontinence worldwide. Stress incontinence and urge incontinence are the two common types of urinary incontinence affecting women, wherein the latter is also known as overactive bladder. Similarly, a study conducted by a group of researchers at the American College of Physicians and Infectious Diseases Society of America in 2020 states urinary tract infection (UTI) are the cause of ~6 million physician visits each year in the US. In Canada, ~500,000 visits to the doctor’s office are for UTI consultations every year. UTI is the eighth and fifth most common reason for ambulatory clinic visits and emergency department visits, respectively, in the country. Thus, the increasing prevalence of urinary incontinence and growing incidence of urinary tract infections are driving the growth of overactive bladder treatment market.

Growth Strategies by the Key Players Operating in the Overactive Bladder Treatment Market:

2022 - Alembic Pharmaceuticals received approval from the US health regulator for its generic version of fesoterodine fumarate extended-release tablets, used for overactive bladder in adults with symptoms of urinary incontinence, urgency, and frequency. The approval by the US Food & Drug Administration (USFDA) for the abbreviated new drug application (ANDA) for fesoterodine fumarate extended-release tablets is for strengths of 4 mg and 8 mg.

2022 - AbbVie company announced that the U.S. Food and Drug Administration (FDA) has approved BOTOX for the treatment of detrusor (bladder muscle) overactivity associated with a neurologic condition in pediatric patients 5 years of age and older who have an inadequate response to or are intolerant of anticholinergic medication.

2022 - Axonics, Inc., a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, announced the comprehensive launch of the Axonics F15 across the United States. The newly developed, long-lived, fully recharge-free sacral neuromodulation (SNM) system received FDA approval in March. The Axonics recharge-free system is a welcome advancement for patients suffering from bladder and bowel dysfunction.

Directly Purchase Premium Copy of Overactive Bladder Treatment Market Growth Report (2022-2028) at: https://www.theinsightpartners.com/buy/TIPRE00004082

2021 - Medtronic plc announced approval from the U.S. Food and Drug Administration (FDA) to proceed with an investigational device exemption (IDE) trial to evaluate its internally developed implantable tibial neuromodulation (TNM) device — a therapy designed to provide relief from symptoms of bladder incontinence.

2020 - Hisamitsu Pharmaceutical Co., Inc. announced the approval of manufacturing and marketing for OABLOK PATCH (Generic name: oxybutynin hydrochloride, hereinafter referred to as “the product”) in Thailand. The product is a systemic transdermal formulation developed using Hisamitsu’s TDDS (Transdermal Drug Delivery System) technology for the treatment of overactive bladder with symptoms such as urinary urgency and frequent urination.

2019 - Teva Pharmaceuticals Ltd. launched Solifenacin Succinate Tablets which are muscarinic antagonist indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency.

Global Overactive Bladder Treatment Market Share Report, Segmentations, Regional & Country Scope:

Browse key market insights spread across 209 pages with 110 list of tables & 80 list of figures from the report, “Overactive Bladder Treatment Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Pharmacotherapy (Anticholinergics, Mirabegron, Botox, Neurostimulation, and Intravesical Instillation) and Disease Type (Idiopathic Overactive Bladder and Neurogenic Bladder)” in detail along with the table of contents: https://www.theinsightpartners.com/reports/overactive-bladder-treatment-market

Urinary incontinence is the loss of bladder control caused due to the improper functioning of the muscles and nerves that control the passage of urine through the bladder. According to the National Association for Incontinence data, in 2018, ~200 million people worldwide were affected by urinary incontinence. Stress incontinence and urge incontinence are the two common types of urinary incontinence affecting women, wherein the latter is also known as overactive bladder. As per the data provided by Office on Women’s Health a division of the US Department of Health and Human Services, the prevalence of incontinence in women is twice as in men, and aging, pregnancy, childbirth, and menopause can be the key factors leading to this condition in women. Other factors affecting the function of muscles and nerves include being overweight, constipation, or pelvic surgeries. As stated by the North American Menopause Society (NAMS), in the US, the prevalence of urinary incontinence was 17.1% among women aged 20 years or more and 38% in women aged 60 years and older in 2021. Although urinary incontinence may affect women at any age, it is more common in older women, mainly due to hormonal changes during menopause. According to the National Health Service (NHS), ~4 in every ten women aged 65 and older have urinary incontinence. As per the HCA UK (a healthcare provider), ~3 million people in the UK are affected by urinary incontinence, of which 15% of women and ~5% of men are in their mid-40s. Thus, the growing prevalence of urinary incontinence favors the growth of the overactive bladder treatment market.

Impact of COVID-19 Pandemic on Global Overactive Bladder Treatment Market Growth:

The COVID-19 pandemic has shown some favorable scenarios for players operating in the overactive bladder treatment market. The US was the highly affected country in North America. The infection severely affected the geriatric population in the country, causing various complications and leading to the death of a large population. For instance, as of May 16, 2022, the US reported 84,230,829 COVID cases with 1,026,670 deaths. Therefore, overactive bladder treatment and proper care are required to prevent chronic cases of infection and health conditions.

After the COVID-19 outbreak, there has been an increase in the occurrence of OAB. According to a study by American Urological Association, patients with COVID-19 infections were at an increased risk for developing new or worsening overactive bladder symptoms. Moreover, approximately one-third of patients with COVID-19 reported a significant increase in clinical symptoms during the International Consultation on Incontinence Questionnaire Overactive Bladder Module (ICIQ-OAB) conducted two months after infection. Out of these one-third of patients, approximately 1 in 5 patients, reported that their OAB symptoms were new. This increased prevalence of OAB due to COVID-19 positively impacted the demand for overactive bladder treatment during the pandemic.

Global Overactive Bladder Treatment Market – Segmentation Overview:

The overactive bladder treatment market is segmented into pharmacotherapy, disease type, and geography. By geography, the market is broadly segmented into North America, Europe, Asia Pacific, the Middle East & Africa, and South & Central America. The overactive bladder treatment market report offers insights and in-depth analysis of the market, emphasizing parameters, such as market trends, market dynamics, and the competitive analysis of the globally leading market players.

Speak To Analyst: https://www.theinsightpartners.com/speak-to-analyst/TIPRE00004082

Based on pharmacotherapy, the overactive bladder treatment market is segmented into mirabegron, Botox, neurostimulation, anticholinergics, and intravesical instillation. The mirabegron segment held the largest share of the market in 2021 and is anticipated to register the highest CAGR during the forecast period. Mirabegron is used alone or with solifenacin to treat overactive bladder in adults. It is used to treat neurogenic detrusor overactivity (a bladder control condition caused by the brain, spinal cord, or nerve problem) in children aged three years or more. Mirabegron belongs to the class of drugs called beta-3 adrenergic agonists. It relaxes the bladder muscles to prevent urgent, frequent, or uncontrolled urination. Mirabegron is available as an extended-release (long-acting) tablet and an extended-release suspension that can be taken orally. In October 2022, Zydus Pharmaceuticals Inc. received approval from the USFDA to market Mirabegron Extended-Release Tablets USP 25 mg and 50 mg.

Go through further research published by The Insight Partners: (Purchase with 10% Instant Discount):

Bladder Scanners Market Forecast to 2028 - Covid-19 Impact and Global Analysis

Bladder Evacuator Market Forecast to 2028 - Covid-19 Impact and Global Analysis

3D Ultrasound Bladder Scanners Market Forecast to 2028 - COVID-19 Impact and Global Analysis

Urine Flow Meters Market Forecast to 2028 - COVID-19 Impact and Global Analysis

About Us:

The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Chemicals and Materials.

Contact Us:

If you have any queries about this report or if you would like further information, please contact us:

Contact Person: Sameer Joshi

E-mail: sales@theinsightpartners.com

Phone: +1-646-491-9876

Press Release: https://www.theinsightpartners.com/pr/overactive-bladder-treatment-market